Search

Your search keyword '"Samiran Panda"' showing total 5 results
Start Over Author "Samiran Panda" Publisher oxford university press (oup)
5 results on '"Samiran Panda"'

1. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern

Author

Gururaj Rao Deshpande, Pragya D Yadav, Priya Abraham, Dimpal A Nyayanit, Gajanan N Sapkal, Anita M Shete, Nivedita Gupta, Krishna Mohan Vadrevu, Raches Ella, Samiran Panda, and Balram Bhargava

Subjects
COVID-19 Vaccines, Vaccines, Inactivated, SARS-CoV-2, COVID-19, Humans, General Medicine, Antibodies, Neutralizing
Abstract

The neutralizing antibody responses were significantly elevated after 3rd dose of BBV152/Covaxin against the B.1 (19.11 fold) variant including Delta (16.51 fold), Beta (14.70 fold) and Omicron (18.53 fold) Variants of concern in comparison with two dose vaccine, providing assurance of a protective immune response of booster in recipients.

Published
2022

2. Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Author

V Krishna Mohan, Dimpal A Nyayanit, Anita M. Shete, Samiran Panda, Balram Bhargava, Pragya D Yadav, Raches Ella, Deepak Y. Patil, Rima R Sahay, Priya Abraham, Gajanan N. Sapkal, Nivedita Gupta, and Gururaj Rao Deshpande

Subjects
0301 basic medicine, Microbiology (medical), 2019-20 coronavirus outbreak, medicine.medical_specialty, Lineage (genetic), Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public health, 030106 microbiology, Antibodies, Viral, Antibodies, Neutralizing, Virology, Neutralization, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Neutralization Tests, Humans, Medicine, 030212 general & internal medicine, business
Abstract

The drastic rise in the number of cases in Maharashtra, India has created a matter of concern for public health experts. Twelve isolates of VUI lineage B.1.617 were propagated in VeroCCL81 cells and characterized. Convalescent sera of the COVID-19 cases and recipients of BBV152 (Covaxin) were able to neutralize VUI B.1.617.

Published
2021

3. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Author

Dimpal A Nyayanit, Kamran Zaman, Samiran Panda, Rajni Kant, Sandeep Chaowdhary, Rima R Sahay, Himanshu Kaushal, Balram Bhargava, Nivedita Gupta, Gaurav Dwivedi, Gajanan Sapkal, Pragya D Yadav, Priya Abraham, Sanjay Kumar, Rajeev Singh, and Gururaj Deshpande

Subjects
COVID-19 Vaccines, Heterologous, Priming (immunology), ChAdOx1 nCoV-19, Research Letter, Humans, Medicine, Adverse effect, Neutralizing antibody, biology, SARS-CoV-2, business.industry, Immunogenicity, COVID-19, Immunogenecity, General Medicine, Virology, Covishield, Vaccination, Regimen, Vaccines, Inactivated, Immunization, Heterologous regime, Covaxin, biology.protein, business, AcademicSubjects/MED00295
Abstract

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.

Published
2021

4. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

Author

Deepak Y. Patil, Pragya D Yadav, Rima R Sahay, Dimpal A Nyayanit, Samiran Panda, Priya Abraham, Sanjay Kumar, Nivedita Gupta, Gururaj Rao Deshpande, Anita M. Shete, Balram Bhargava, and Gajanan N. Sapkal

Subjects
BBV152, Delta, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19, General Medicine, Antibodies, Neutralizing, Virology, Neutralization, Vaccination, Variant of concern, Titer, Neutralization Tests, Research Letter, Humans, Medicine, Delta AY.1, business, AcademicSubjects/MED00295
Abstract

Sera of COVID-19 naive vaccinees, COVID-19 recovered cases with vaccination and breakthrough cases demonstrated 1.3-, 2.5- and 1.9-fold reduction in neutralization titers against Delta and 1.5-, 3.5- and 2.8-fold against Delta AY.1 compared with B.1, respectively. However, high-neutralization titers would still effectively protect against Delta, Delta AY.1 and B.1.617.3 variants.

Published
2021

5. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Author

Nivedita Gupta, Dimpal A Nyayanit, Samiran Panda, Rima R Sahay, Balram Bhargava, Raches Ella, V Krishna Mohan, Priya Abraham, Pragya D Yadav, Deepak Y. Patil, Gururaj Rao Deshpande, Anita M. Shete, and Gajanan N. Sapkal

Subjects
Delta, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Beta, COVID-19, vaccine efficacy, General Medicine, neutralization, Vaccine efficacy, Antibodies, Neutralizing, Virology, Neutralization, Humans, Medicine, business, Beta (finance), AcademicSubjects/MED00295, Rapid Communication
Abstract

SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-19 recovered cases and BBV152 vaccinees against Beta and Delta variants. BBV152 vaccine found to confer significant protection against both the variants.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results